Hologic, Inc. $HOLX Shares Sold by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio reduced its stake in Hologic, Inc. by 6.0%, selling 4,430 shares during the 2nd quarter, bringing its total to 69,256 shares valued at approximately $4.5 million.
• Hologic's stock has received multiple price target upgrades from analysts, with Citigroup increasing their target from $60 to $80 after upgrading the stock from "neutral" to "buy."
• CEO Stephen P. Macmillan sold 138,358 shares of Hologic at an average price of $66.97, decreasing his ownership by 10.08%, while retaining over 1.2 million shares valued at approximately $82.7 million.

Public Employees Retirement System of Ohio cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 69,256 shares of the medical equipment provider's stock after selling 4,430 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Hologic were worth $4,513,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Fifth Third Bancorp increased its position in shares of Hologic by 5.9% during the 2nd quarter. Fifth Third Bancorp now owns 26,974 shares of the medical equipment provider's stock valued at $1,758,000 after purchasing an additional 1,496 shares during the period. Golden State Equity Partners bought a new stake in shares of Hologic during the 2nd quarter worth $410,000. GAMMA Investing LLC boosted its stake in shares of Hologic by 129.4% during the 2nd quarter. GAMMA Investing LLC now owns 7,269 shares of the medical equipment provider's stock worth $474,000 after acquiring an additional 4,100 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Hologic by 38.3% during the 2nd quarter. Farther Finance Advisors LLC now owns 2,538 shares of the medical equipment provider's stock worth $165,000 after acquiring an additional 703 shares in the last quarter. Finally, CX Institutional boosted its stake in shares of Hologic by 16.1% during the 2nd quarter. CX Institutional now owns 3,693 shares of the medical equipment provider's stock worth $241,000 after acquiring an additional 513 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HOLX. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Morgan Stanley raised their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Finally, Wall Street Zen raised Hologic from a "hold" rating to a "buy" rating in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and an average price target of $79.38.

Insider Transactions at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Price Performance

HOLX opened at $67.15 on Tuesday. The stock has a market cap of $14.94 billion, a price-to-earnings ratio of 27.86, a PEG ratio of 2.44 and a beta of 0.57. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a fifty day moving average price of $66.83 and a 200 day moving average price of $62.94.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.